There are plenty of reasons to envy Grail, the Google-backed company seeking to revolutionize how cancer is diagnosed. The company has raised more than $1 billion, pulled off a series of high-profile hires, and made a splash in the New England Journal of Medicine.
But organizational stability may not be one of them.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
